… This review mainly focuses on the level one evidence-based clinical efficacy and drug-related
toxicity of oral PDE5Is. In addition, drug discovery, pharmacokinetics and …

… Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and …
be weak inhibitors of PDE, but to what extent this contributed toward their clinical efficacy was …

… and clinical efficacy of PDE4 inhibitors, which have been in clinical development over the
years are summarized with specific emphasis on their clinical pharmacokinetic properties. …

… In this chapter, alternative means of harnessing the clinical efficacy of PDE4 inhibitors
are described. These concepts are based on the assumption that additive or synergistic anti-…

… clinical studies in the previous 3 months. xiii) A history of allergies to specific phosphodiesterase
inhibitors … load dose may reduce adverse reactions without affecting its clinical efficacy. …

… The growing number of phosphodiesterase inhibitors that are selective for … clinical efficacy
in vivo. In addition, because of overlapping affinities with other PDEs, each PDE5 inhibitor will …

Objectives. In a randomized double‐blind crossover trial, we compared the efficacy of
phosphodiesterase‐5 (PDE‐5) inhibitor tadalafil with placebo in patients of Eisenmenger …

… Some instruments for comparison of clinical efficacy have to be considered subjective (psychometry,
patient’s preference, changes in quality of general, or sexual life). Some others are …

… In this review, we aimed to assist clinicians in their assessment of the onset and duration of
efficacy of sildenafil, vardenafil, and tadalafil using pharmacokinetic data and clinical studies. …

… inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5
inhibition … show positive results and efficacy with PDE5 inhibition despite no safety concerns. …